AVASTIN® (Bevacizumab injection 100mg/400mg) is a tumor-starving (anti-angiogenic) therapy. AVASTIN® is designed to block a protein called vascular endothelial growth factor, or VEGF. Normal cells make VEGF, but some cancer cells make too much VEGF. Blocking VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors.
Unlike chemotherapy that attacks the cancer cells, the purpose of AVASTIN® is to block the blood supply that feeds the tumor. This can stop the tumor from growing.
AVASTIN® has a clinically meaningful activity in six distinct tumor types. AVASTIN® is indicated in advanced cancers like metastatic Colorectal Cancer (mCRC), platinum resistant Ovarian Cancer (PROC), recurrent, persistent or metastatic Cervical Cancer (CC), non-squamous Non-Small Cell Lung Cancer (nsNSCLC), recurrent Glioblastoma (rGBM), and metastatic renal cell carcinoma (mRCC).
Click Here to view the complete prescribing information.